Houston Methodist. Leading Medicine.
Houston Methodist. Leading Medicine

Clinical Trials

Clinical Trials at The Methodist Hospital Research Institute

Search results...

Cancers and Other Neoplasms

Active and enrolling clinical trials for Cancers and Other Neoplasms are updated on this page as they become available. You are also welcome to view our clinical trials that are registered with the National Institutes of Health.
 
For more information please contact the study coordinator of the trials listed below or contact the main clinical trials help line 713-441-3250.
 
Brain and Central Nervous System Cancers

NovoCure EF-14
Study Status: Active/Enrolling
Investigator: New, Pamela
Study Coordinator: Harris, Kimbra
Phone: 713-441-3834
Summary:The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatm...(read more)

RTOG 0929
Study Status: Active/Enrolling
Investigator: New, Pamela
Study Coordinator: Harris, Kimbra
Phone: 713-441-3834
Summary:RATIONALE: ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide. work in different ways to stop the growt...(read more)
Brain Cancers

NovoCure EF-14
Study Status: Active/Enrolling
Investigator: New, Pamela
Study Coordinator: Harris, Kimbra
Phone: 713-441-3834
Summary:The study is a prospective, randomly controlled pivotal trial, designed to test the efficacy and safety of a medical device, the NovoTTF-100A, as an adjuvant to the best standard of care in the treatm...(read more)
Breast Cancers

CA216.001 BMS906024 in Subjects With Advanced or Metastatic Solid Tumor
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies.(read more)

CAT Trial
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The major purpose of this research study is to better understand how therapy works on different patients. This study is being offered to patients with a diagnosis of advanced or metastatic breast canc...(read more)

Denosumab - Breast Cancer
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:Purpose: This randomized phase 3 trial is studying the effect of denosumab to see if it can prevent disease recurrence in the bone or in any other part of the body, when it is given as adjuvant therap...(read more)

Ganetespib STA-9090 for Metastatic HER2 Positive or Triple Negative Breast Cancer
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The purpose of this study is to determine if ganetespib (STA-9090) is effective in the treatment of patients with HER2+ or triple negative breast cancer who have not received prior systemic treatment ...(read more)

ICE Trial
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:Ixabepilone and capecitabine combination has demonstrated to be an active regimen in patients with metastatic breast cancer (MBC) after failing an anthracycline and a taxane regimen. Cetuximab is acti...(read more)

Katherine, B50, for Treatment of Adjuvant HER2 Positive Breast Cancer
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:This 2-arm, randomized, open-label study will evaluate the efficacy and safety of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have res...(read more)

M12-895 Abbott Phase II
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The Study Evaluating Efficacy And Tolerability of Veliparib in Combination with Temozolomide or Veliparib/Placebo in Combination with Carboplatin and Paclitaxel in Subjects with Breast Cancer Gene (BR...(read more)

NECTAR Everolimus plus Cisplatin in Triple (-) Breast Cancer
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:PURPOSE: The purpose of this study is to test how effective combing a Cisplatin chemotherapy with Everolimus is in treating subjects with residual triple negative breast cancer, who have already recei...(read more)

NSABP B43
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or...(read more)

NSABP B47
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination ch...(read more)

Olive Oil for Breast Cancer Prevention in Women at High Risk for Breast Cancer
Study Status: Active/Enrolling
Investigator: Patel, Tejal
Study Coordinator: Bass, Anastasia
Phone: 713-441-8389
Summary:This is a pilot study is evaluating the effect of hydroxytyrosol, a component of Olive oil, on mammographic density in women at high risk of breast through assessing whether mammographic density is re...(read more)

PREDATOR TRIAL
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:The purpose of this phase II study is to find out if the test, Mammostrat® can be used as a predictor or outcome tool to determine who will best benefit from chemotherapy prior to surgery. This can be...(read more)

PROMIS registry of mammaprint in breast cancer
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:This is a prospective registry study that will assess the impact of MammaPrint on chemotherapy + endocrine versus endocrine alone treatment decisions in patients with an Oncotype Intermediate Score.(read more)

REP0210: Reparixin in early breast cancer patients prior to surgery
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:This is a pilot "window of opportunity" clinical study in patients with operable breast cancer investigating use of reparixin as single agent in the time period between clinical diagnosis and surgery....(read more)

S0812 Vitamin D in High Risk Breast Cancer
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:RATIONALE: Cholecalciferol may prevent breast cancer in premenopausal women. PURPOSE: This randomized phase II trial is studying how well cholecalciferol works in preventing breast cancer in premenop...(read more)

SWOG 1007
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy, using tamoxifen citrate, may fight breast cancer by blocking the use of estrogen by the tumor cells. Aromatase inhibit...(read more)

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects
Study Status: Active/Enrolling
Investigator: Rodriguez, Angel
Study Coordinator: Salazar, Maria
Phone: 713-441-6011
Summary:The purpose of this study is to compare active immunotherapy (OPT-822/OPT-821) with PBS in combination with low dose cyclophosphamide, in post-treated metastatic breast cancer subjects with stable dis...(read more)

Triple Negative RAD 001
Study Status: Active/Enrolling
Investigator: Chang, Jenny
Study Coordinator: Boone, Toniva
Phone: 7134410686
Summary:RATIONALE: Drugs used in chemotherapy, such as cisplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Everol...(read more)
Colon and Colorectal Cancer

CA216.001 BMS906024 in Subjects With Advanced or Metastatic Solid Tumor
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies.(read more)
Hematologic Cancers

ENDEAVOR Carfilzomib and Dexamethasone Versus Velcade and Dexamethasone for Relapsed Multiple Myeloma Patients
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:This Phase 3 study is a multicenter, open-label, randomized trial in patients with multiple myeloma whose disease has relapsed after at least 1 but not more than 3 prior therapeutic regimens. Patients...(read more)

GDC-0199 and Obinutuzumab in Chronic Lymphocytic Leukemia
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Dotting , Andrea
Phone: 713-441-8029
Summary:This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics of GDC-0199 (ABT-199) administered in combination with obinutuzumab to patients with relapsed/refractory...(read more)
Lung Cancers

CA216.001 BMS906024 in Subjects With Advanced or Metastatic Solid Tumor
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:The purpose of this study is to identify a safe and tolerable dose of BMS-906024 in subjects with advanced or metastatic solid tumors who no longer respond to or have relapsed from standard therapies.(read more)

GALAXY 2 TRIAL Ganetespib w/Docetaxel vs Docetaxel alone in patients w/advanced NSCLC
Study Status: Active/Enrolling
Investigator: Bernicker, Eric
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:The purpose of this study is to determine whether combining ganetespib (STA-9090) with docetaxel is more effective than docetaxel alone in the treatment of patients with advanced non-small cell lung c...(read more)

LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib
Study Status: Active/Enrolling
Investigator: Bernicker, Eric
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:The primary purpose of the study is to compare the antitumor activity of LDK378 vs. chemotherapy in patients previously treated with chemotherapy (platinum doublet) and crizotinib.(read more)

OAK TRIAL - MPDL3280A with Docetaxel in Patients with Non-Small Cell Lung Cancer After Failure with Platinum-Containing Chemotherapy
Study Status: Active/Enrolling
Investigator: Bernicker, Eric
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:This global, multicenter, open-label, randomized, controlled study will evaluate the efficacy and safety of MPDL3280A compared with docetaxel in patients with locally advanced or metastatic non-small ...(read more)

S0819 Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab w/ or w/out Cetuximab in Patients with NSCLC
Study Status: Active/Enrolling
Investigator: Bernicker, Eric
Study Coordinator: Bieniemy, Dana
Phone: 713-441-0629
Summary:RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Mono...(read more)
Lymphoma

C14012: Alisertib or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:This is a phase 3, randomized, 2-arm, open-label, international trial evaluating alisertib compared with single-agent treatment, as selected by the investigator from the offered options of pralatrexat...(read more)

GDC-0199 and Obinutuzumab in Chronic Lymphocytic Leukemia
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Dotting , Andrea
Phone: 713-441-8029
Summary:This multi-center, open-label, dose-finding study will evaluate the safety and pharmacokinetics of GDC-0199 (ABT-199) administered in combination with obinutuzumab to patients with relapsed/refractory...(read more)

MLN8237 in Relapsed or Refractory Aggressive B-Cell Lymphoma - C14011
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Woodard, Karen
Phone: 713-441-4332
Summary:This is a single-arm, open-label, multicenter, dose escalation, phase 1-2 study of alisertib (MLN8237) administered in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)/transf...(read more)

OMB113676 Head to Head Trial of Ofatumumab versus Rituximab
Study Status: Active/Enrolling
Investigator: Iyer, Swaminathan
Study Coordinator: Logan, Catherine
Phone: 713-441-0629
Summary:This is a multi-center, parallel, active comparator controlled, open-label, randomized (1:1) phase III study of single agent ofatumumab compared to single agent rituximab in subjects with rituximab-se...(read more)
Ovarian & Fallopian Tube Cancers

GOG-0225
Study Status: Active/Enrolling
Investigator: Kamat, Aparna
Study Coordinator: Kamath, Jaya
Phone: 713-441-6616
Summary:This randomized phase III trial is studying diet and physical activity changes to see how well they work compared with usual care in improving progression-free survival of patients with previously tre...(read more)
Prostate Cancers

LUTS Pilot - VESI-11E02
Study Status: Active/Enrolling
Investigator: Boone, Timothy
Study Coordinator: Whipple, Melissa
Phone: 713-441-3247
Summary:A single center, pilot trial with combination therapy of tamsulosin and solifenacin in 20 men with symptomatic lower urinary tract symptoms (LUTS). Subjects will be evaluated at baseline, 1, 2, and 3 ...(read more)